VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita — VALO-2

Pachyonychia Congenita Clinical Trial

Official title:
VALO-2: A Multicenter, Phase 3b, Open-Label Treatment Extension Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita

Status Active, not recruiting

Clinical Trial Summary

VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is included to evaluate safety and efficacy of patients with genotyped keratin mutations of KRT6C and KRT17 not previously treated with investigational PTX-022.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pachyonychia Congenita

Clinical Trial Details

NCT number	NCT04520750
Study type	Interventional
Source	Palvella Therapeutics, Inc.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 1, 2020
Completion date	January 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02592954` - Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin	Phase 1
Recruiting	`NCT05180708` - A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita	Phase 3
Recruiting	`NCT05643872` - A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita	Phase 3
Recruiting	`NCT05956314` - Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC	Phase 1
Not yet recruiting	`NCT01382511` - Simvastatin Treatment of Pachyonychia Congenita	N/A
Completed	`NCT02152007` - Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)	Phase 1
Completed	`NCT00716014` - Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita	Phase 1
Recruiting	`NCT02321423` - International Pachyonychia Congenita Research Registry
Active, not recruiting	`NCT03920228` - Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita	Phase 2/Phase 3